Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.31 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198240 | 0.94 | TLR4 (0.46) | TLR4ENPP2SMPD1CYP3A4MAPT | |
| SCHEMBL4205820 | 0.90 | TLR4 (0.44) | TLR4ENPP2NR5A2NR5A1 | |
| SCHEMBL4199865 | 0.86 | TLR4 (0.45) | TLR4ENPP2 | |
| SCHEMBL4198761 | 0.85 | TLR4 (0.52) | TLR4ENPP2SMPD1NR5A2NR5A1 | |
| SCHEMBL4200285 | 0.83 | TLR4 (0.43) | TLR4ENPP2NR5A2NR5A1 | |
| SCHEMBL4195266 | 0.83 | TLR4 (0.50) | TLR4ENPP2NR5A2NR5A1 | |
| SCHEMBL4201319 | 0.83 | TLR4 (0.50) | TLR4ENPP2NR5A2NR5A1 | |
| SCHEMBL4201320 | 0.83 | TLR4 (0.50) | TLR4ENPP2NR5A2NR5A1 | |
| SCHEMBL4199322 | 0.83 | TLR4 (0.44) | TLR4ENPP2 | |
| SCHEMBL4195538 | 0.82 | TLR4 (0.43) | TLR4ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | TLR4 294/4885ENPP2 68/4885SMPD1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.